Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of once-weekly oral NBI-1065846 for anhedonia in major depressive disorder has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• NBI-1065846

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Anhedonia, Major Depressive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2024-07-31